This study is a clinical, multi-center, retrospective, case-control study. Patients clinically diagnosed with severe anthrax who meet the inclusion and exclusion criteria will be included in this study for analysis. Respiratory, circulation, nerve and other vital signs of patients with severe anthrax during hospitalization were recorded, and clinical data such as blood routine, blood biochemistry, coagulation function, myocardial injury, therapeutic drug use, and survival time of patients were recorded, as well as the survival situation of patients 28 days and 90 days after discharge.
Study Type
OBSERVATIONAL
Enrollment
80
Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
RECRUITINGmortality rates of severe anthrax
mortality rates of severe anthrax
Time frame: 28 days and 90 days
incidence of complications
To evaluate the incidence of respiratory, circulatory, neurological, digestive, coagulation and other complications of severe anthrax
Time frame: in hospital
Peripheral blood biomarkers associated with 28-day and 90-day mortality
Peripheral blood biomarkers associated with 28-day and 90-day mortality
Time frame: 28 days and 90 days
the improvement in 28-day and 90-day mortality with treatment for severe anthrax
the improvement in 28-day and 90-day mortality with treatment for severe anthrax
Time frame: 28 days and 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.